Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07612813 | A Study to Evaluate the Safety and Pharmacokinetics of AZD7760 in Healthy Japanese Adults | PHASE1 | NOT YET_RECRUITING | 18 | — | — | Jun 24, 2026 | Sep 24, 2027 | May 29, 2026 | 1 | Japan |
To evaluate the safety of AZD7760 administered as a single IV Dose A or Dose B in healthy Japanese adult participants.
To evaluate the safety of AZD7760 administered as a single IV Dose A or Dose B in healthy Japanese adult participants.
| Arm | Type | Description |
|---|---|---|
| Cohort 1 (AZD7760 Dose A) | EXPERIMENTAL | Participants receive an IV infusion of AZD7760 Dose A on Day 1. |
| Cohort 2 (AZD7760 Dose B) | EXPERIMENTAL | Participants receive an IV infusion of AZD7760 Dose B on Day 1. |
| Pooled Placebo | PLACEBO_COMPARATOR | Participants receive an IV infusion of matching placebo on Day 1. |
| Name | Type | Description |
|---|---|---|
| AZD7760 | DRUG | Participants will receive AZD7760 via IV infusion. |
| Placebo | OTHER | Participants will receive matching placebo via IV infusion. |
Inclusion Criteria: * Body weight ≥ 45 kg and ≤ 110 kg and BMI within the range of ≥ 18.0 to ≤ 30.0 kg/m2 (inclusive) at screening. * Healthy Japanese participants with no clinically significant concomitant diseases or medications. Exclusion Criteria: * Known hypersensitivity to any component of ...